share_log

BTIG Upgrades Aclaris Therapeutics to Buy, Announces $8 Price Target

BTIG Upgrades Aclaris Therapeutics to Buy, Announces $8 Price Target

BTIG将aclaris therapeutics评级上调为买入,目标价定为8美元
Benzinga ·  2024/11/19 09:46  · 评级/大行评级

BTIG analyst Julian Harrison upgrades Aclaris Therapeutics (NASDAQ:ACRS) from Neutral to Buy and announces $8 price target.

BTIG分析师朱利安·哈里森将Aclaris Therapeutics(纳斯达克股票代码:ACRS)从中性上调至买入,并宣布目标股价为8美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发